Detalhe da pesquisa
1.
Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells.
Cytotherapy
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38727653
2.
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Biol Blood Marrow Transplant
; 23(1): 53-59, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27771496
3.
ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Ann Hematol
; 93(10): 1745-53, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24863692
4.
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Bone Marrow Transplant
; 59(3): 359-365, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38167647
5.
Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.
Haematologica
; 98(3): 437-43, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22899581
6.
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
Cancers (Basel)
; 15(5)2023 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900400
7.
Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk.
bioRxiv
; 2023 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36712139
8.
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk.
Cells
; 12(15)2023 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37566035
9.
Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review.
Adv Rheumatol
; 62(1): 33, 2022 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35999577
10.
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
Blood Cancer J
; 14(1): 83, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38760376
11.
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.
Leuk Res
; 40: 1-9, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26598032